Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 8 of 8 for “"ALK inhibitors"”.

  1. Functional identification of molecular oncotargets associated with the resistance to ALK inhibition in neuroblastoma via genome-wide CRISPR-Cas9 screens

    … have identified Anaplastic Lymphoma Kinase (ALK) as the only directly ‘druggable’ target with a significant mutation rate (9%). ALK is a receptor tyrosine kinase whose dysregulation has been implicated as the driver lesion in a variety of cancer types, including Non-Small Cell Lung Cancer …

    cambridge Repository record for Functional identification of molecular oncotargets associated with the resistance to ALK inhibition in neuroblastoma via genome-wide CRISPR-Cas9 screens (opens in a new tab)

  2. ALK in the pathogenesis of cancer

    Anaplastic Lymphoma Kinase (ALK) has been implicated in the pathogenesis of many types of cancer including Anaplastic Large Cell Lymphoma (ALCL) and neuroblastoma (NB). ALK is an ideal drug target as its endogenous expression is limited to neuronal cells during neonatal development, although …

    cambridge Repository record for ALK in the pathogenesis of cancer (opens in a new tab)

  3. Modelling RANBP2-ALK-rearranged Epithelioid Inflammatory Myofibroblastic Sarcoma

    … myofibroblastic tumour characterised by ALK staining that is perinuclear or cytoplasmic with perinuclear accentuation, CD30 expression and early relapse despite crizotinib treatment [1, 2]. This study aimed to generate and utilise models of eIMS to assess molecular-targeted therapeutic …

    unsw Repository record for Modelling RANBP2-ALK-rearranged Epithelioid Inflammatory Myofibroblastic Sarcoma (opens in a new tab)

  4. Investigating the Genomics and Heterogeneity of Childhood Non-Hodgkin Lymphoma

    … improving overall survival, and the use of ALK inhibitors such as crizotinib have been used to successfully bridge relapsed or refractory ALCL patients to stem cell transplantation---however, resistance to both ALK inhibitors and Rituximab occurs in the clinic. Therefore, there is urgent …

    cambridge Repository record for Investigating the Genomics and Heterogeneity of Childhood Non-Hodgkin Lymphoma (opens in a new tab)

  5. Novel treatment strategy for ALK-positive Anaplastic Large Cell Lymphoma

    Anaplastic Lymphoma Kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) is a T-cell non-Hodgkin lymphoma characterised by a chromosomal rearrangement [t(2;5) (p23;q25)] involving the ALK and NPM1 genes on chromosomes 2 and 5 respectively. This translocation generates the NPM-ALK fusion …

    cambridge Repository record for Novel treatment strategy for ALK-positive Anaplastic Large Cell Lymphoma (opens in a new tab)

  6. Studying the Transcriptional and Epigenetic Perturbations of Haematopathologies Expressing NPM1-ALK

    Anaplastic lymphoma kinase (ALK) is a tyrosine kinase involved in the development of the gut and nervous system, initially cloned from cases of T-cell lymphoma. ALK has been frequently implicated in diverse cancers through oncogenic translocations, mutations, chromosomal inversion, or amplification …

    cambridge Repository record for Studying the Transcriptional and Epigenetic Perturbations of Haematopathologies Expressing NPM1-ALK (opens in a new tab)